Immune cell therapy plus drug shows promise in advanced melanoma pilot
NCT ID NCT01701674
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested a new combination treatment for people with advanced melanoma that has spread. It combined a patient's own immune cells grown in a lab (called TILs) with an immunotherapy drug called ipilimumab. The main goals were to see if the treatment was safe and possible to give. Only 13 people took part, so the results are very early and need more research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma